Bullement, Ash http://orcid.org/0000-0001-7091-0972
Nathan, Paul http://orcid.org/0000-0002-5612-8439
Willis, Anna http://orcid.org/0000-0003-4795-4795
Amin, Amerah http://orcid.org/0000-0001-5558-5390
Lilley, Cameron http://orcid.org/0000-0002-4647-6085
Stapelkamp, Ceilidh http://orcid.org/0000-0002-2707-3790
Hatswell, Anthony http://orcid.org/0000-0003-1129-326X
Pescott, Chris http://orcid.org/0000-0002-7763-9326
Bharmal, Murtuza http://orcid.org/0000-0001-7689-5769
Funding for this research was provided by:
Merck KGaA, Darmstadt, Germany
Pfizer
Article History
First Online: 24 January 2019
Compliance with Ethical Standards
:
: Murtuza Bharmal and Chris Pescott are employees of Merck KGaA, Darmstadt, Germany; Ceilidh Stapelkamp and Amerah Amin are employees of EMD Serono, Northwood, UK. At the time of the study, Ash Bullement and Anthony Hatswell were employees of BresMed, who were a paid consultant to Merck KGaA, Darmstadt, Germany. Anna Willis and Cameron Lilley are employees of BresMed, who were a paid consultant to Merck KGaA, Darmstadt, Germany. Paul Nathan received consulting fees for advisory boards for Merck KGaA and Pfizer.
: This study was funded by and is part of an alliance between Merck KGaA and Pfizer, Inc., NY, USA.